Diabetes: the place of new therapies

Therapeutic Advances in Endocrinology and Metabolism
Ketan Dhatariya

Abstract

Until the discovery of insulin in 1921 there were no effective treatments for diabetes mellitus. After the advent of long-acting insulin, the first oral agents, sulfonylureas became available in the mid-1950s, quickly followed (outside of the United States) by metformin. It was then another three decades before newer agents became available, with alpha glucosidase inhibitors, thiazolidinediones and meglitinides following in the 1990s. Since the turn of the century, several new classes have also been launched. But how do these agents fit into the management of type 2 diabetes? How does one choose which drug class to use after metformin? This review looks at the agents launched since 2000 and how and when they can be used. It also deals with some of the controversies that have arisen and how decisions have changed as a result, in particular moving away from the use of HbA1c as the driver for decision, but rather the cardiovascular safety of these agents and their use in the prevention of premature cardiovascular morbidity and mortality. Now that some of these agents have shown cardiovascular benefit, will this lead to a change in the treatment paradigm?

References

Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Apr 28, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·D C WhitelawM Nattrass
Nov 7, 1959·Lancet·D JACKSON, W OAKLEY
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Sep 8, 2010·BMJ : British Medical Journal·Deborah Cohen
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Dec 30, 2011·BMJ : British Medical Journal·John S YudkinVictor M Montori
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Apr 16, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Yehuda HandelsmanMatthew R Weir
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jul 28, 2016·Diabetes/metabolism Research and Reviews·Jianping WengUNKNOWN Chinese Diabetes Society
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Apr 5, 2017·The Lancet. Diabetes & Endocrinology·Ketan K Dhatariya, Guillermo E Umpierrez
Jun 13, 2017·The New England Journal of Medicine·Steven P MarsoUNKNOWN DEVOTE Study Group
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 5, 2017·Diabetologia·Clifford J Bailey
Sep 14, 2017·The New England Journal of Medicine·Satish K GargPaul Strumph
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Sep 25, 2017·Diabetes Research and Clinical Practice·Ketan K Dhatariya
Apr 11, 2018·Diabetic Medicine : a Journal of the British Diabetic Association·H SimsJ Minguet
May 8, 2018·Diabetes, Obesity & Metabolism·Helen J CurtisBen Goldacre
Jul 30, 2018·BMJ Open·Samantha WilkinsonLaurie Tomlinson

❮ Previous
Next ❯

Citations

May 1, 2021·Biology·Sophia KelainiAndriana Margariti
Jun 3, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kristina S BoyeJay Patrick Bae

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
amputations

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2022 Meta ULC. All rights reserved